Literature DB >> 6457989

On the mutagenicity of nitroimidazoles.

C E Voogd.   

Abstract

Regarding mutagenicity, metronidazole is one of the best-investigated compounds of the nitroimidazoles. This drug is mutagenic on bacteria, especially if base-pair tester strains are used and bacterial nitroreductases are present. The serum levels attained in man after intake of this drug are sufficient to cause mutations in bacteria. Furthermore, interaction with and binding to DNA occurs under anaerobic conditions and sometimes DNA breaks are observed. However, metronidazole does not show mutagenic activity in mammalian cells in vitro; the micronucleus test is negative and chromosome aberrations are only found under anaerobic conditions. With microbial systems the mutagenicity of 47 nitroimidazoles has been investigated. Only 4 compounds were always negative in the applied test systems. Because with base-pair tester strains mutagenicity was assessed, this class of compounds should be regarded as a base-pair mutagen. In fungi, some compounds (e.g. ZK 26173 and azathioprine) are potent mutagens, whilst with most investigated nitroimidazoles only a weak or no mutagenic activity could be detected. Somewhat similar observations have been made in tests with Drosophila melanogaster, a test for gene mutations in mammalian cells, the micronucleus test, cytogenic tests and the dominant lethal test. The reduction products of metronidazole, misonidazole and 1-methyl-2-nitro-5-vinylimidazole, cause DNA damage if the nitro group is reduced in the presence of DNA. Reduction products are formed by microbes in the gut or by mammalian cells under anaerobic conditions. No teratological effect due to metronidazole or most other nitroimidazoles has been observed. Metronidazole is carcinogenic in mice and rats, and dimetridazole in rats. Up to the present, no carcinogenic effects have been observed in man. Azathioprine is probably carcinogenic for man. It is unlikely that the therapeutic applications of the presently used nitroimidazoles, except for azathioprine, will cause an increase in the tumor incidence in man or will cause other genotoxic effects, although such effects cannot be excluded with certainty.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6457989     DOI: 10.1016/0165-1110(81)90006-3

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  13 in total

1.  In vivo efficacy of albendazole against Giardia duodenalis in mice.

Authors:  J A Reynoldson; R C Thompson; B P Meloni
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

2.  Validity of silver, chitosan, and curcumin nanoparticles as anti-Giardia agents.

Authors:  D E Said; L M Elsamad; Y M Gohar
Journal:  Parasitol Res       Date:  2012-03-06       Impact factor: 2.289

3.  Evidence for enzymatic reduction of 1-nitropyrene by rat liver fractions.

Authors:  J P Nachtman; E T Wei
Journal:  Experientia       Date:  1982-07-15

Review 4.  Nitroimidazoles for the treatment of TB: past, present and future.

Authors:  Tathagata Mukherjee; Helena Boshoff
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

Review 5.  Treatment of giardiasis.

Authors:  T B Gardner; D R Hill
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

6.  Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.

Authors:  Sidharth Chopra; Gary A Koolpe; Arlyn A Tambo-Ong; Karen N Matsuyama; Kenneth J Ryan; Tran B Tran; Rupa S Doppalapudi; Edward S Riccio; Lalitha V Iyer; Carol E Green; Baojie Wan; Scott G Franzblau; Peter B Madrid
Journal:  J Med Chem       Date:  2012-06-25       Impact factor: 7.446

Review 7.  Functionalized Nitroimidazole Scaffold Construction and Their Pharmaceutical Applications: A 1950-2021 Comprehensive Overview.

Authors:  Ria Gupta; Sumit Sharma; Rohit Singh; Ram A Vishwakarma; Serge Mignani; Parvinder Pal Singh
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-30

8.  Metronidazole decreases viability of DLD-1 colorectal cancer cell line.

Authors:  Anna Sadowska; Rafał Krętowski; Beata Szynaka; Marzanna Cechowska-Pasko; Halina Car
Journal:  Cancer Biother Radiopharm       Date:  2013-06-18       Impact factor: 3.099

9.  Comparative evaluation of the 2-methyl-5-nitroimidazole compounds dimetridazole, metronidazole, secnidazole, ornidazole, tinidazole, carnidazole, and panidazole against Bacteroides fragilis and other bacteria of the Bacteroides fragilis group.

Authors:  L Jokipii; A M Jokipii
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

10.  Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.

Authors:  Els Torreele; Bernadette Bourdin Trunz; David Tweats; Marcel Kaiser; Reto Brun; Guy Mazué; Michael A Bray; Bernard Pécoul
Journal:  PLoS Negl Trop Dis       Date:  2010-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.